[1]张贺 杨立英 黄雯莉 王文昭 陈素凤 任路平.长链非编码RNA与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2020,40(04):241-243248.[doi:10.3760/cma.j.issn.1673-4157.2020.04.006]
 Zhang He,Yang Liying,Huang Wenli,et al.Long non-coding RNA and non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(04):241-243248.[doi:10.3760/cma.j.issn.1673-4157.2020.04.006]
点击复制

长链非编码RNA与非酒精性脂肪性肝病
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年04期
页码:
241-243248
栏目:
综述
出版日期:
2020-07-20

文章信息/Info

Title:
Long non-coding RNA and non-alcoholic fatty liver disease
作者:
张贺12 杨立英12 黄雯莉12 王文昭12 陈素凤12 任路平12
1河北医科大学,石家庄 050017; 2河北省人民医院内分泌代谢病一区,石家庄 050051
Author(s):
Zhang He12 Yang Liying12 Huang Wenli12 Wang Wenzhao12 Chen Sufeng12 Ren Luping12
1Hebei Medical University, Shijiazhuang 050017, China; 2Endocrine and Metabolic Disease Area 1, Hebei General Hospital, Shijiazhuang 050051, China
关键词:
非酒精性脂肪性肝病 长链非编码RNA 甘油三酯脂肪酶 类固醇受体RNA激活剂
Keywords:
Non-alcoholic fatty liver Long non-coding RNA Fatty triglyceride lipase Steroid receptor RNA activator
DOI:
10.3760/cma.j.issn.1673-4157.2020.04.006
摘要:
LncRNA是由200多个核苷酸组成的转录产物,缺乏蛋白质编码能力。近年来lncRNAs已成为多种生物过程的重要调控因子,广泛参与了许多生物学过程,包括细胞分化、肿瘤发生、免疫反应、肝脏脂代谢和其他生物学过程。LncRNA可以调控多种基因表达,影响肝细胞内脂代谢,进而参与非酒精性脂肪性肝病的发生、发展,包括通过影响肝脏脂质合成、脂肪酸β氧化、通过microRNA调节某些靶点以及对肝脏基因的表观遗传调控来发挥作用。
Abstract:
LncRNA is a transcription product consisting of more than 200 nucleotides, which lacks the ability to encode proteins. In recent years, lncRNAs have become important regulators of various biological processes, and have been widely involved in many biological processes, including stem cell pluripotency, embryogenesis, cell differentiation, liver lipid metabolism and other biological processes. LncRNA can regulate the expression of a variety of genes and affect lipid metabolism in liver cells, and then participate in the development of non-alcoholic fatty liver disease. These include effects on liver lipid synthesis, fatty acid beta oxidation, regulation of certain targets by microRNA, and epigenetic regulation of liver genes.

参考文献/References:

[1] Zhang Q, Wang J, Li H, et al. LncRNA Gm12664-001 ameliorates nonalcoholic fatty liver through modulating miR-295-5p and CAV1 expression[J].Nutr Metab(Lond),2020,17:13.DOI:10.1186/s12986-020-0430-z.
[2] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases[J].Cell Metab,2018,27(1):22-41.DOI:10.1016/j.cmet.2017.08.002.
[3] Day CP, James OF.Steatohepatitis:a tale of two "hits"?[J]. Gastroenterology,1998,114(4):842-845.DOI:10.1016/s0016-5085(98)70599-2.
[4] Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152.DOI:10.1172/JCI22422.
[5] Fan C, Tang Y, Wang J, et al. Role of long non-coding RNAs in glucose metabolism in cancer[J].Mol Cancer, 2017,16(1):130.DOI:10.1186/s12943-017-0699-3.
[6] Guo J, Cai H, Zheng J, et al. Long non-coding RNA NEAT1 regulates permeability of the blood-tumor barrier via miR-181d-5p-mediated expression changes in ZO-1, occludin, and claudin-5[J]. Biochim Biophys Acta Mol Basis Dis, 2017,1863(9):2240-2254.DOI:10.1016/j.bbadis.2017.02.005.
[7] Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs[J].Cell, 2007,129(7):1311-1323.DOI:10.1016/j.cell.2007.05.022.
[8] Lanz RB, McKenna NJ, Onate SA, et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex[J].Cell,1999,97(1):17-27.DOI:10.1016/j.cell.2007.05.022.
[9] Ong KT, Mashek MT, Bu SY, et al. Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning[J].Hepatology, 2011,53(1):116-126.DOI:10.1002/hep.24006.
[10] Wu JW, Wang SP, Alvarez F, et al.Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis[J].Hepatology,2011,54(1):122-132.DOI:10.1002/hep.24338.
[11] Haemmerle G, Lass A, Zimmermann R, et al.Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase[J].Science, 2006,312(5774):734-737.DOI:10.1126/science.1123965.
[12] Chen G, Yu D, Nian X, et al. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase(ATGL)[J].Sci Rep,2016,6(1).DOI:10.1038/srep35531.
[13] Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009,136(2):215-233.DOI:10.1016/j.cell.2009.01.002.
[14] Ikarashi N, Toda T, Okaniwa T,et al. Anti-obesity and anti-diabetic effects of acacia polyphenol in obese diabetic kkay mice fed high-fat diet[J].Evid Based Complement Alternat Med, 2011,2011:952031.DOI:10.1093/ecam/nep241.
[15] Zhang M, Chi X, Qu N, et al. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis[J]. Biochem Biophys Res Commun,2018,499(1):66-70.DOI:10.1016/j.bbrc.2018.03.127.
[16] Zhao XY, Li S, Wang GX, et al. A long noncoding RNA transcriptional regulatory circuit drives thermogenic adipocyte differentiation[J]. Mol Cell,2014,55(3):372-382.DOI:10.1016/j.molcel.2014.06.004.
[17] Zhao XY, Xiong X, Liu T, et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis[J]. Nat Commun, 2018,9(1):2986.DOI:10.1038/s41467-018-05383-2.
[18] Sun Y, Song Y, Liu C, et al. LncRNA NEAT1-microRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling[J]. Biochem Biophys Res Commun, 2019,516(2):584-590. DOI:10.1016/j.bbrc.2019.06.104.
[19] Wang X, Zou M, Li J, et al. LncRNA H19 targets miR-22 to modulate H2 O2-induced deregulation in nucleus pulposus cell senescence, proliferation, and ECM synthesis through Wnt signaling[J]. J Cell Biochem,2018,119(6):4990-5002.DOI:10.1002/jcb.26738.
[20] Liu J, Tang T, Wang GD, et al. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARgamma axis in non-alcoholic fatty liver disease[J]. Biosci Rep, 2019,39(7):BSR20181722.DOI:10.1042/BSR20181722.
[21] Sookoian S, Rohr C, Salatino A, et al. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease[J].Oncotarget, 2017,8(14):22917-22926.DOI:10.18632/oncotarget.15286.
[22] Sun C, Liu X, Yi Z, et al.Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease[J].IUBMB Life, 2015,67(11):847-852.DOI:10.1002/iub.1442.

相似文献/References:

[1]张晓燕,陈莉明.儿童非酒精性脂肪性肝病研究进展[J].国际内分泌代谢杂志,2007,(04):289.
[2]贺肴,张弛,刘瑛,等.代谢正常肥胖合并非酒精性脂肪性肝病的临床特征及内皮功能研究[J].国际内分泌代谢杂志,2015,(03):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
 He Yao,Zhang Chi,Liu Ying,et al.Clinical features and endothelial function in metabolically healthy obese patients with nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2015,(04):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
[3]邵金双,邸阜生.网膜素抗炎作用及与代谢相关疾病的关系[J].国际内分泌代谢杂志,2014,(01):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
 Shao Jinshuang*,Di Fusheng ..Anti-inflammatory effect of omentin and its relationship with metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
[4]王兴纯,曲伸.胰高血糖素样肽-1受体激动剂与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(01):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
 Wang Xingchun*,Qu Shen.Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
[5]黄玥晔,曲伸.甲状腺激素受体:非酒精性脂肪性肝病的新靶点[J].国际内分泌代谢杂志,2014,(01):43.[doi:10.3760/cma.j.issn.1673-4157.2014.01.012]
 Huang Yueye,Qu Shen.Thyroid hormone receptor:a new target of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):43.[doi:10.3760/cma.j.issn.1673-4157.2014.01.012]
[6]蔡芸莹,苏恒.DPP-4在脂质代谢及非酒精性脂肪性肝病中的作用研究[J].国际内分泌代谢杂志,2014,(02):112.[doi:10.3760/cma.j.issn.1673-4157.2014.02.012]
 Cai Yun-ying,Su Heng..Effects of dipeptidyl peptidase-4 on lipid metabolism and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):112.[doi:10.3760/cma.j.issn.1673-4157.2014.02.012]
[7]李爱玲,谢云,李瑾,等.体重指数和腰臀比预测非酒精性脂肪性肝病发病风险的比较[J].国际内分泌代谢杂志,2014,(02):135.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]
 Li Ailing,Xie Yun,Li Jin,et al.Comparison of body mass index and waist-to-hip ratio for predicting of non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):135.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]
[8]方迎昕 周一军.长链非编码RNA与胰岛素抵抗的关系[J].国际内分泌代谢杂志,2018,38(06):412.[doi:10.3760/cma.j.issn.1673-4157.2018.06.013]
 Fang Yingxin,Zhou Yijun.Relationship between long non-coding RNA and insulin resistance[J].International Journal of Endocrinology and Metabolism,2018,38(04):412.[doi:10.3760/cma.j.issn.1673-4157.2018.06.013]
[9]马卓奇 敖娜 都健.线粒体相关microRNA在非酒精性脂肪性肝病中的研究进展[J].国际内分泌代谢杂志,2019,39(05):307.[doi:10.3760/cma.j.issn.1673-4157.2019.05.005]
 Ma Zhuoqi,Ao Na,Du Jian.Research progress of mitochondria-related microRNA in non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2019,39(04):307.[doi:10.3760/cma.j.issn.1673-4157.2019.05.005]
[10]韦茂英,晏蔚田,魏璠,等.非编码RNA在糖尿病认知障碍中的作用[J].国际内分泌代谢杂志,2020,40(06):420.[doi:10.3760/cma.j.cn121383-20200322-03060]
 Wei Maoying,Yan Weitian,Wei Fan,et al.Effects of non-coding RNA in diabetic cognitive impairment[J].International Journal of Endocrinology and Metabolism,2020,40(04):420.[doi:10.3760/cma.j.cn121383-20200322-03060]

备注/Memo

备注/Memo:
通信作者:任路平,Email:renluping1122@163.com
Corresponding author: Ren Luping, Email:renluping1122@163.com
更新日期/Last Update: 2020-07-20